Table 3.

Univariate and multivariate Cox proportional hazard regression analysis for recurrence

	Univariate analysis					Multivariate analysis
Factors	HR	95% CI	p			HR	95% CI	p
Training cohort (n=64)
Age
(≥70 vs. <70)	1.50	0.78–2.89	0.22
Gender
(Male vs. Female)	0.87	0.44–1.72	0.70
Hepatitis virus infection
(Positive vs. Negative)	0.68	0.28–1.64	0.39
Liver cirrhosis
(Cirrhosis vs. Non-cirrhosis)	1.70	0.87–3.34	0.12
Tumor location
(Perihilar vs. Peripheral)	1.74	0.88–3.42	0.11
Tumor size
(≥35mm vs. 35mm)	1.69	0.83–3.43	0.15
Bile duct type
(Large vs. Small)	2.03	1.01–4.06	0.05			1.53	0.74–3.15	0.25
CEA
(≥5.0ng/mL vs. <5.0ng/mL)	1.83	0.96–3.49	0.07			1.80	0.93–3.49	0.08
CA19–9
(≥37U/mL) vs. <37U/mL)	1.79	0.93–3.45	0.08			1.72	0.87–3.41	0.12
Vascular invasion
(Positive vs. Negative)	1.90	0.99–3.65	0.06			1.79	0.91–3.53	0.09
Adjuvant chemotherapy
(Positive vs. Negative)	0.86	0.45–1.67	0.67
RNA panel
(High risk vs. Low risk)	3.22	1.62–6.42	<0.01			2.87	1.42–5.81	<0.01
Validation cohort (n=177)
Age
(≥70 vs. <70)	1.09	0.74–1.59	0.67
Gender
(Male vs. Female)	1.24	0.88–3.42	0.11
Hepatitis virus infection
(Positive vs. Negative)	0.70	0.45–1.10	0.12
Liver cirrhosis
(Cirrhosis vs. Non-cirrhosis)	1.28	0.86–1.90	0.23
Tumor location
(Perihilar vs. Peripheral)	1.14	0.74–1.76	0.54
Tumor size
(≥35mm vs. 35mm)	2.35	1.59–3.47	<0.01			1.46	0.95–2.22	0.08
Bile duct type
(Large vs. Small)	1.37	0.93–2.01	0.11
CEA
(≥5.0ng/mL vs. <5.0ng/mL)	1.57	1.03–2.41	0.04			1.04	0.68–1.57	0.87
CA19–9
(≥37U/mL) vs. <37U/mL)	2.17	1.48–3.20	<0.01			1.35	0.88–2.08	0.17
Vascular invasion
(Positive vs. Negative)	2.15	1.46–3.17	<0.01			1.39	0.92–2.10	0.12
Adjuvant chemotherapy
(Yes vs. No)	1.45	0.97–2.18	0.07
RNA panel
(High risk vs. Low risk)	2.73	1.86–4.01	<0.01			1.58	1.02–2.46	0.04
Risk model
(High risk vs. Low risk)	6.08	3.55–10.41	<0.01			3.49	1.81–6.71	<0.01

CA19–9, Carbohydrate antigen 19–9; CEA, Carcinoembryonic antigen; CI, confidence interval; HR, hazard ratio